Prognostic value of positron emission tomography/computed tomography in transplant-eligible newly diagnosed multiple myeloma patients from CASSIOPEIA: the CASSIOPET study

Françoise Kraeber-Bodéré; Sonja Zweegman; Aurore Perrot; Cyrille Hulin; Denis Caillot; Thierry Facon; Xavier Leleu; Karim Belhadj; Emmanuel Itti; Lionel Karlin; Clément Bailly; Mark-David Levin; Monique C Minnema; Bastien Jamet; Caroline Bodet-Milin; Bart De Keizer; Marie C Béné; Hervé Avet-Loiseau; Pieter Sonneveld; Lixia Pei; Fabio Rigat; Carla De Boer; Jessica Vermeulen; Tobias Kampfenkel; Jérôme Lambert; Philippe Moreau

doi:10.3324/haematol.2021.280051

Prognostic value of positron emission tomography/computed tomography in transplant-eligible newly diagnosed multiple myeloma patients from CASSIOPEIA: the CASSIOPET study

Haematologica. 2023 Feb 1;108(2):621-626. doi: 10.3324/haematol.2021.280051.

Authors

Françoise Kraeber-Bodéré¹, Sonja Zweegman², Aurore Perrot³, Cyrille Hulin⁴, Denis Caillot⁵, Thierry Facon⁶, Xavier Leleu⁷, Karim Belhadj⁸, Emmanuel Itti⁹, Lionel Karlin¹⁰, Clément Bailly¹¹, Mark-David Levin¹², Monique C Minnema¹³, Bastien Jamet¹⁴, Caroline Bodet-Milin¹¹, Bart De Keizer¹⁵, Marie C Béné¹⁶, Hervé Avet-Loiseau¹⁷, Pieter Sonneveld¹⁸, Lixia Pei¹⁹, Fabio Rigat²⁰, Carla De Boer²¹, Jessica Vermeulen²¹, Tobias Kampfenkel²¹, Jérôme Lambert²², Philippe Moreau²³

Affiliations

¹ Service de Médecine Nucléaire, University Hospital Hôtel-Dieu, Nantes, France; CRCI2NA, INSERM, CNRS, Université d'Angers, Nantes Université, Nantes. francoise.bodere@chu-nantes.fr.
² Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Department of Hematology, Amsterdam.
³ CHU de Toulouse, IUCT-O, Université de Toulouse, UPS, Service d'Hématologie, Toulouse.
⁴ Department of Hematology, Hôpital Haut Lévêque, University Hospital Bordeaux, Pessac.
⁵ CHU Dijon, Hôpital du Bocage, Dijon.
⁶ University of Lille, CHU Lille, Service des Maladies du Sang, Lille.
⁷ CHU Poitiers, Hôpital la Milétrie, Poitiers.
⁸ Hôpital Henri Mondor, Lymphoid Malignancies Unit, Créteil.
⁹ Department of Nuclear Medicine, Hôpital Henri Mondor, Créteil.
¹⁰ Centre Hospitalier Lyon-Sud Hématologie (HCL), Pierre-Bénite.
¹¹ Service de Médecine Nucléaire, University Hospital Hôtel-Dieu, Nantes, France; CRCI2NA, INSERM, CNRS, Université d'Angers, Nantes Université, Nantes.
¹² Albert Schweitzer Ziekenhuis, Dordrecht.
¹³ Department of Hematology, University Medical Center Utrecht, Utrecht.
¹⁴ Service de Médecine Nucléaire, University Hospital Hôtel-Dieu, Nantes.
¹⁵ Department of Nuclear Medicine and Radiology, University Medical Center Utrecht, Utrecht.
¹⁶ CRCI2NA, INSERM, CNRS, Université d'Angers, Nantes Université, Nantes, France; Hematology Biology, University Hospital Hôtel Dieu, Nantes.
¹⁷ Unite de Génomique du Myelome, IUC-Oncopole, Toulouse.
¹⁸ Erasmus MC Cancer Institute, Rotterdam.
¹⁹ Janssen Research and Development, LLC, Raritan, NJ.
²⁰ Janssen Research and Development, LLC, Buckinghamshire.
²¹ Janssen Research and Development, LLC, Leiden.
²² Biostatistical Department, Hôpital Saint Louis, Paris.
²³ CRCI2NA, INSERM, CNRS, Université d'Angers, Nantes Université, Nantes, France; Hematology, University Hospital Hôtel-Dieu, Nantes.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Fluorodeoxyglucose F18
Humans
Multiple Myeloma* / diagnostic imaging
Positron Emission Tomography Computed Tomography / methods
Positron-Emission Tomography
Prognosis
Radiopharmaceuticals

Substances

Fluorodeoxyglucose F18
Radiopharmaceuticals

Associated data

ClinicalTrials.gov/NCT02541383

Grants and funding

Funding: This study was funded by the Intergroupe Francophone du Myélome (IFM) and the Dutch-Belgian Cooperative Trial Group for Hematology Oncology (HOVON) and was supported in part by grants from the French National Agency for Research called “Investissements d’Avenir” IRON Labex n° ANR-11-LABX-0018-01 and by a grant from INCa-DGOS-Inserm_12558 (SIRIC ILIAD).